Royalty Pharma (RPRX) reported Q3 net income Wednesday of $544 million, up from $72 million a year earlier.
Comparable analysts' estimates were not available.
Total income and other revenue for the quarter ended Sept. 30 was $565 million, up from $536 million a year earlier.
Three analysts polled by Capital IQ expected $731.8 million.
As of Sept. 30, the company said it had $950 million in cash and cash equivalents.
Royalty Pharma shares were up 3.1% in recent Wednesday premarket activity.
Price: 27.94, Change: +0.84, Percent Change: +3.10
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。